`
`APPLICA TI0N NUMBER:
`
`50-790 / 8-002
`
`' APPROVAL LETTER
`
`
`
`silvlc
`a,”
`
`93‘“
`
`g: .6 DEPARTMENTOFHEALTH&HUMANSERVICES
`
`1,,
`
`publicHealthService
`
`Food and Drug Administration
`Rockville, MD 20857
`
`NDA 50-790/S-002
`
`Allergan, Inc.
`Attention: Elizabeth Bancrofi
`
`Senior Director, Regulatory Affairs
`2525 Dupont Drive
`PO. Box 19534
`
`Irvine, California 92623-9534
`
`Dear Ms. Bancroft:
`
`Please refer to your supplemental new drug application dated June 27,. 2003, received June 30, 2003,
`submitted under the Federal Food, Drug, and'Cosmetic Act for Restasis (cyclosporine ophthalmic
`emulsion), 0.05%.
`'
`
`This application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the
`FDA Modernization Act of 1997.
`
`We acknowledge receipt of your submission dated July 29, 2003.
`
`p This “Changes Being Effected in 30 days” supplemental new drug application provides an additional
`
`We completed our review of this supplemental new drug application, as amended. This supplement is
`_ approved.
`
`-
`
`’We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR
`314.80 and 314.81).
`‘
`,
`
`If you have any questions, call Lori M. Gorski, Regulatory Project Manager, at (301) 827-2090.
`
`Sincerely,
`
`{See appended electronic signature page}
`
`Linda L. Ng, Ph.D.
`Chemistry Team Leader, for the
`Division of Anti-Inflammatory, Analgesic ’
`and Ophthalmic Drug Products, HFD-550
`DNDC III, Office of New Drug Chemistry
`Center for Drug Evali1ation and Research
`
`
`
`This is a representation of an electronic record that was signed electronically and
`this page is the manifestation of the electronic signature.
`
`Linda Ng
`9/12/03 05:24:23 PM
`
`